• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Hyderabad, July 31

Aurobindo Pharma’s first-quarter profit after tax (PAT) has risen 61.7 per cent to Rs 58.54 crore against Rs 36.21 crore in the corresponding previous period. Total income grew 22.1 per cent to Rs 512.91 crore (Rs 420.17 crore). The formulations business grew 28.3 per cent to Rs 134.3 crore, with exports growing 10 per cent to Rs 277.2 crore. During the quarter, the firm spent Rs 39.94 crore on R&D expenses, compared to Rs 14.16 crore earlier. The increase was du e to the decision to charge the entire R&D expenses on product development to profit and loss account instead of capitalisation as intangibles, according to a release. On Tuesday, the Aurobindo Pharma shares closed 0.99 per cent lower at Rs 652 on the BSE.

– Our Bureau

More Stories on : Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
BOC India Q1 sales, net down

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line